The Role of Liposomal CpG ODN on the Course of L. major Infection in BALB/C Mice
-
H Hejazi
,
M Tasbihi
,
MR Jaafari
,
A Badiee
,
N Pestechian
,
A Javadi
,
A Khamesipour
Abstract
Background: Historically, leishmanization is the most effective protective measure against Cutaneous Leishmaniasis (CL), CL lesion induced by leishmanization sometimes takes a long time to heal. Manipulation of leishmanization inoculums needed to induce a mild and acceptable CL lesion. The aim of this study was to explore if liposomal form of CpG ODN (Cytosin phosphate Guanin Oligodeoxynucleotides) mixed with Leishmania major would induce a milder lesion size in Balb/c mice.
Methods: This study was performed in Biotechnology Research Center, Mashhad, and Center for Research and Training in Skin Diseases and Leprosy, Tehran, Iran during 2008-2009. mice were subcutaneously (SC) inoculated with L. major mixed with liposomal form of CpG ODN, or L. major plus free CpG ODN, or L. major mixed with empty liposomes or L. major in PBS. The lesion onset and the size of lesion were recorded; the death rate was also monitored.
Result: Footpad thickness was significantly (P<0.01) smaller, death rate was also significantly (P<0.05) lower in the mice received L. major mixed with liposomal CpG ODN or free CpG ODN than control groups received L. major in PBS or L. major plus liposomes, also mice which received L. major mixed with CpG ODN in soluble form showed a significantly (P < 0.001) smaller lesion size than control groups.
Conclusion: CpG ODN seems to be an appropriate immunopotentiator mixed with Leishmania stabilate in leishmanization.
Leishmaniasis- disease information. World Health Organization, Geneva Switzerland. 2004 Available from: http://www.who.int/tdr/disease/leish/di seaseinfo.html
Daneshvar H, Graham H. Coombs, Hagan P, Stephen Phillips R. Leishmania mexicana and Leishmania major:Attenuation of wild-type parasites and vaccination with the attenuated lines. Infect Dis. 2003; 187:1662–8.
Khamesipour A, Rafati S, Davoudi N, Mahboudi F. Leishmaniasis vaccine candidates for development: a global overview. Indian J Med Res. 2006; 123: 423-27.
Rivier D, Shah R, Bovay P, Mauel J. Vaccine development against cutaneous leishmaniasis. Subcutaneous administration of radioattenuated parasites protects CBA mice against virulent Leishmania major challenge. Parasite Immunol. 1993; 15:75-84.
Khamesipour A, Dowlati Y, Asilian A, Hashemi-Fesharki R, Javadi A, Noazin S, Modabber F. Leishmanization: Use of an old method for evaluation of candidate vaccines against leishmaniasis. Vaccine. 2005;n 23:3642-8.
Noazin S, Modabber F, Khamesipour A et al. First generation leishmaniasisvaccines: A review of field efficacy trials. Vaccine. 2008; 26: 6759-67.
Noazin S, Khamesipour A, Moulton LH et al. Efficacy of killed wholeparasite vaccines in the prevention of leishmaniasis: a meta-analysis. Vaccine. 2009; 27: 4747-53.
Nadim A, Javadian E, Tahvildari-Bidruni GH, Ghorbani M. Effectiveness of leishmanization in control of cutaneous leishmaniasis. Bull Soc Path Exot. 1983; 76:397-383.
Nadim A, Javadian E, Mohebali M. The experience of leishmanization in the Islamic Republic of Iran. East Mediterr Health J. 1997; 3:284-289.
Greenblatt CL. The present and future of vaccination for cutaneous leishmaniasis. Prog Clin Biol Res. 1980; 47:259-285.
Klinman DM, Currie D, Gurse I, Verthelyi D. Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol Rev. 2004; 199:201-16.
Krieg A M. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol. 2002; 20: 709-760.
Rhee EG, Mendez S, Shah JA, Wu CY, Kirman JR, Turon TN, Davey DF, Davis H, Klinman DM, Coler RN, Sacks DL, Seder RA. Vaccination with Heat-killed Leishmania Antigen or Recombinant Leishmanial Protein and CpG Oligodeoxynucleotides induces long-term memory CD4+and CD8+ Tcell responses and protection against Leishmania major infection. J Exp Med. 2002; 195: 1565-1573.
Iborra S, Parody N, Abánades DR, Bonay P, Prates D, Novais FO, Barral- Netto M, Alonso C, Soto M. Vaccination with the Leishmania major ribosomal proteins plus CpG oligodeoxynucleotides induces protection against experimental cutaneous leishmaniasis in mice. Microbes Infect. 2008; 10:1133-41.
Zimmermann S, Egeter O, Hausmann S, Lipford GB, Röcken M, Wagner H, Heeg K. Cutting Edge: CpG Oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J Immunol. 1998; 160: 3627-3630.
Gregoriadis G. Immunological adjuvant: a role for liposomes. Immunol Today. 1990;11:89-97.
Jaafari MR, Ghafarian A, Farrokh- Gisour A, Samiei A, Kheiri MT, Mahboudi F, Barkhordari F, Khamesipour A, McMaster WR. Immune response and protection assay of recombinant major surface glycoprotein of Leishmania (rgp63) reconstituted with liposomes in BALB/c mice. Vaccine. 2006; 24:5708-5717.
Jaafari MR, Badiee A, Khamesipour, A, Samiei A, Soroush D, Kheiri MT, Barkhordari F, McMaster WR, Mahboudi F. The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome. Vaccine. 2007; 25: 6107-6117.
Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV. CpG oligodeorynucleotide act as adjuvants that switch on T helper1 (Thl) immunity. J Exp Med. 1997; 186:1623-1631.
Kibrey C, Gregoriadis G. Dehydration- Rehydration Vesicle: a simple method for high yield drug entrapment in liposomes. Biotechnology. 1984; 2: 979-84.
Brunner C, Seiderer J, Schlamp A, Bidlingmaier M, Eigler A, Haimerl W, Lehr HA, Krieg AM, Hartmann G, Endres S. Enhanced dendritic cell, maturation by TNF-α or cytidin-phosphate- guanosine DNA derived T cell activation in vitro and therapeutic antitumor immune responses in vivo. J Immunol. 2000; 165:6278-6286.
Tighe H, Takabayashi K, Schwartz D, Van Nest G, Tuck S, Eiden JJ, Kagey- Sobotka A, Creticos PS, Lichtenstein LM, Spiegelberg HL, Raz E. Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clinm Immunol. 2000; 106:124-134.
Davis HL, Suparto II, Weeratna RR, Jumintarto, Iskandriati DD, Chamzah SS, Ma'ruf AA, Nente CC, Pawitri DD, Krieg AM, Heriyanto, Smits W, Sajuthi DD. CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine. 2000 ; 18:1920-1924.
Elkins KL, Rhinehart-Jones TR, Stibitz S, Conover JS, Klinman DM. Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. J Immunol.1999; 162:2291-2298.
Gramzinski RA, Doolan DL, Sedegah M, Davis HL, Krieg AM, Hoffman SL. Interleukin-12-and δ interferon – dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice. Infect Immun. 2001; 69:1643-1649.
Mendez S, Tabbara K, Belkaid Y, Bertholet S, Verthelyi D, Klinman D, Seder RA, Sacks DL . Coinjection with CpG-Containing Immunostimulatory oligodeoxtnucleotides reduces the pathogenicity of a live vaccine against cutaneous leishmaniasis but maintains its potency and durability. Infect Immun. 2003; 71:5121-5129
Sacks D, Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol. 2002; 2:845-854.
Gregoriadis G, Florence A.T, Patel H.M (Eds). Liposomes in Drug Delivery, pp. 77-94 1993.
Ahmad-Nejad P, Hacker H, Rutz M, Bauer S, Vabulas RM, Wagner H. Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur J Immunol. 2002; 32:1958–68.
| Files | ||
| Issue | Vol 5 No 1 (2010) | |
| Section | Articles | |
| Keywords | ||
| CpG ODN Liposome Leishmania major BALB/c | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
